PAHO Revolving Fund: Regional Demand Pooling Perspectives

PAHO/WHO Call for EOI Vaccine Tech Transfer Hub

9 June 2021
1977

CD25.R27 “Establishment of the Expanded Program on Immunization (EPI) and the PAHO Revolving Fund”.

2013

CD52R5 “Principles of the PAHO Revolving Fund for Vaccine Procurement and CD52/15 “Review of the Charge Assessed on the Procurement of Public Health Supplies for Member States”.

2014

CD53/23 Report “PAHO Revolving for vaccine procurement: Challenges and Opportunities”.

2017

CSP29/16 “Situation update on the challenges of supplying IPV to maintain polio eradication in the Region”.

PAHO Member States’ Resolutions: Reg. Immunization Program & Revolving Fund
The Revolving Fund forms part of PAHO’s comprehensive technical support involving demand planning - procurement dimensions to ensure access to affordable and assured quality vaccines, syringes and cold chain equipment.
Operations guided by:

- Immunization technical program
- Established demand planning process
- Economies of scale
- Lowest-single price
- Transformational agenda

Benefits and services to Member States

- Access to credit
- Financial Sustainability
- International bids
- Quality control
- "Catalyst" for a sustainable uptake of new products
- Access
- International Logistics
- Transparency
- Reduced regulatory provisions
- Legislation
- Affordability
- Strengthened national budget lines
- Continuous improvement
- Regional solidarity, purpose, & ownership by MS
- Evidence-based decision-making processes

How?

PAHO’s Sustainability Model for National Immunization Programs

National Plans: Vaccine Forecasts (PAHO 173)

Revolving Fund Mechanism: "Facilitating Access" to Vaccines at Affordable Prices

National Financing: Budgets & Legislation

- Pooled procurement approach – economies of scale
- Apply tech criteria to guide supply allocation minimizing risks of shortages; coordinate loans of vaccines to countries
- Keep countries informed on global vaccine market dynamics
- Building capacity in countries on demand planning and financial sustainability
- Monitor technical eligibility of vaccines & respond to claims
- Leveraging capital fund and credit line for country financing
- Transform customer value proposition, key processes, key resources & sustainability/turnover formula
UTILIZATION OF INFORMATION

ANNUAL DEMAND COLLECTION WITH MEMBER STATES (PAHO-173)

- Database Feeding
- Calculation of Capital Needs
- Regional demand consolidation by product
- Information for Tenders
- Order Placement Follow-Up
- Report Generation
- Supplier Allocation

- Calculating regional demand by product
- Generating orders and follow-up
- Providing information for tenders
- Feeding database with regional demand information
- Calculating capital needs for tenders
- Allocation of suppliers
* Globally, the Americas has been the leading region in uptake and delivery of influenza vaccines

**Switch from NH to SH formulation:**
- Colombia (2007)
- El Salvador (2011)*
- Cuba (2015)
- Honduras (2015)
- Costa Rica (2015)

**Switch from SH to NH formulation:**
- Dominica (2016)
- Guatemala (2018)
- Suriname (2019)

RF as a Key Pillar of PAHO’s technical cooperation

“One pillar contributing to the success for immunization in the Americas”

1979 - 2021
Collecting and leveraging demand
42 years

Vaccination coverage in the Americas
93%
For Diphtheria, Tetanus-pertussis
$750 Million
procured in 2020

Over 95% of vaccine costs covered with national funds

75 million
vaccinated by the National Immunization Programs annually.

46 vaccines
29 Syringes & cold chain products
31 Providers

41 Countries and territories of Latin America and the Caribbean


COVAX deliveries – data as of June 8

LATAM & Caribbean
GLOBAL

<table>
<thead>
<tr>
<th>Countries served</th>
<th>129</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume and Doses</td>
<td>78.1 M</td>
</tr>
</tbody>
</table>
Access is not equal across PAHO RF Member States

Percentage of population covered by existing agreements (May 2021)

- Caribbean and AMC Member States are being left behind
- Access in Brazil and Cuba is heavily dependent on the success of national manufacturers

**30 % or less**
- Haiti
- Jamaica
- Nicaragua
- Argentina
- Barbados
- The Bahamas
- Belize
- Grenada
- Guyana
- Honduras
- St. Kitts and Nevis
- St Lucia
- St Vincent and the Grenadines
- Suriname
- Trinidad and Tobago
- Venezuela

**30 % - 50%**
- Antigua and Barbuda
- Bolivia
- Colombia
- Costa Rica
- Dominica
- Ecuador
- El Salvador
- Panama
- Paraguay
- Uruguay
- Brazil
- Chile
- Cuba (*pending* Soberana-02)
- Dominican Republic
- Guatemala
- Mexico
- Peru

**95% or more**

**NOTES**
- Overseas territories are not included (the Netherlands and the UK have committed to providing vaccine to cover the full population)
- Does not include doses procured through African Medical Supplies Platform (AMSP)
- Based on supply agreements known to PAHO; there is limited visibility into future donations and bilateral deals
- No adjustment for coverage or wastage; adjusted for doses in schedule
COVID-19 Vaccine demand dynamics are rapidly evolving and will continue to change

- Target populations
- Public health objectives
- Control and prevention of transmission (vaccine + other)
  - WHO SAGE, PAHO TAG
- Budgetary/fiscal constraints
  - CVIC tool and partners platform

VIRUS EVOLUTION & EPIDEMIOLOGY
- Variants of concern
- Requirements for boosters or next generation vaccines
  - WHO R&D blueprint
  - WHO SAGE, PAHO TAG

NATIONAL COVID-19 STRATEGY & FINANCING
- Duration of protection
- Cold chain, storage and handling conditions
- Expansion of target populations (e.g. pregnant, children)
  - WHO SAGE, WHO EUL

SUPPLY AGREEMENTS (COVAX, BILATERAL DEALS, DONATIONS, ETC)
- COVAX participation ratios for 2021
- COVAX dose sharing and cost sharing
- N% Covered by bilateral agreements, donations, licensing agreements
  - WHO manufacturing taskforce
  - COVAX 2022+ and supplier strategies
  - COVID-19 Vaccine Market Assessment (WHO, UNICEF, Gavi, BMGF, PAHO)

NATIONAL IMMUNIZATION PROGRAMS
- Delivery capacity to reach target populations
  - Supply chain complexity
  - Wastage rates
- Adverse reactions
  - Acceptability and uptake
  - PAHO TAG

VACCINE PROFILE

PAHO
Understanding Supply & Market Dynamics

Ratio of deals per country population
https://launchandscalefaster.org/COVID-19

Pipeline Products and Regulatory Pathways

Mapping Tech. Transfer & Regional Opportunities

- Continued engagement with the COVAX Facility and global partners
- Monitoring global supply projections and availability
- Facilitating intra-regional dose-sharing
- Identification of optimal product preferences and affordability options for PAHO MS

Monitoring Bilateral Deals
Demand scenarios for COVID-19 vaccines in 2022 and beyond

- 2022 supply will depend on strategies to address variants (e.g. multivalent vaccines) and signals from global strategy (anticipated demand will impact scale-up plans and potential exit from the market).
- Currently, the WHO SAGE position that there is not yet conclusive evidence on vaccine protection against VOCs
- **Current unknowns and future dynamics will require interactive demand planning and supply matching approach in 2022 and beyond. PAHO RF role will be critical to ensure demand X supply match.**

<table>
<thead>
<tr>
<th>Overall Demographic Estimates in Latin American and Caribbean Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>650 M</td>
</tr>
</tbody>
</table>

PAHO
Upcoming: Online COVID-19 Vaccine Demand Mapping Platform

**Purpose:** to forecast demand for COVID-19 vaccines in Member States for 2021 and 2022

**Components of the tool:**
- Verify **target population and prioritisation** *(who do you aim to vaccinate?)*
- Verify **supply agreements** *(what is your anticipated vaccine supply?)*
- **Forecast additional vaccine needs** for 2021 and 2022
- Express initial vaccine preferences

**Outcome:** the information will inform the PAHO strategy for equitable access to COVID-19 vaccines, including scenario building for demand in 2022 and beyond
The role of the Revolving Fund in Global Initiatives and Opportunities for Member States to engage in the COVAX facility through PAHO Revolving Fund.

Revolving Fund data infographic

Media contacts
Sebastian Oiel | Daniel Epstein | Nancy Nusser
mediateam@paho.org

https://www.paho.org/en/revolvingfund
https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Jan2021_v2.pdf
https://www.paho.org/en/